Condition: Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation · Sponsor: NYU Langone Health
This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced KRASG12C mutant non-small cell lung cancer (NSCLC).
This description comes directly from the study's public registry record.
Salman Punekar, MD · 212 731 6228 · Salman.punekar@nyulangone.org
Always discuss trial participation with your own doctor first.
| NYU Langone Health | Garden City, New York, United States | Recruiting |
| NYU Langone Health | Mineola, New York, United States | Recruiting |
| NYU Langone Health | New Hyde Park, New York, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05815173